: Locoregional recurrence after mastectomy: incidence and outcomes. Patients who received neratinib and capecitabine had significantly improved PFS (HR, 0.76; 95% CI, 0.630.93). Gonzalez-Angulo AM, Hortobagyi GN: Optimal schedule of paclitaxel: weekly is better. : Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Jassem J, Piekowski T, Puzaska A, et al. Br Med J (Clin Res Ed) 284 (6319): 869-70, 1982. Median PFS was significantly longer in the talazoparib group than in the standard therapy group (8.6 months vs. 5.6 months; HR. J Clin Oncol 39 (13): 1485-1505, 2021. J Clin Oncol 33 (7): 709-15, 2015. Lancet Oncol 19 (1): 27-39, 2018. : Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. : American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. : Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. Grade 3 to 4 neutropenia occurred in 53.4% of patients in the ribociclib group and 0.0% of patients in the placebo group. Frontiers | Pathologic response and survival after neoadjuvant [, At the second interim analysis, the median follow-up was 25.9 months in the pembrolizumab-and-chemotherapy group and 26.3 months in the placebo-and-chemotherapy group. : Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. J Clin Oncol 41 (2): 198-205, 2023. Ann Oncol 29 (9): 1939-1947, 2018. : Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. Multifocal and multicentric breast cancer, whether the conservative treatment is enough? In a phase III trial, patients with metastatic disease [, A series of N Engl J Med 386 (12): 1143-1154, 2022. : Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. However, there are few studies investigating the therapeutic and prognostic impact of such heterogeneity. [, In patients with a PD-L1 CPS of 10 or more, the median OS was 12.7 months (95% CI, 9.916.3) in the pembrolizumab group and 11.6 months (95% CI, 8.313.7) in the chemotherapy group (HR, 0.78; 95% CI, 0.571.06; log-rank, In patients with a CPS of 1 or more, the median OS was 10.7 months (95% CI, 9.312.5) in the pembrolizumab group and 10.2 months (95% CI, 7.912.6) in the chemotherapy group (HR, 0.86; 95% CI, 0.691.06; log-rank. Mastectomy Still Standard Blum JL, Jones SE, Buzdar AU, et al. : The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. : Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. : Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients. : Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. The primary PFS analysis from the phase III. : Prevalence and mutational determinants of high tumor mutation burden in breast cancer. multicentric breast cancer WebBreast cancer treatment commonly includes various combinations of surgery, radiation therapy, chemotherapy, and hormone therapy. Ann Oncol 24 (9): 2278-84, 2013. van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. widespread disease, but, in a subset of patients, it may be the only site of : MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Henderson IC: A rose is no longer a rose. Rugo HS, Diras V, Gelmon KA, et al. Radiother Oncol 31 (1): 33-40, 1994. Leonard R, Hardy J, van Tienhoven G, et al. Breast Cancer Res Treat 174 (3): 719-729, 2019. Cancer 50 (7): 1235-44, 1982. : Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Ann Oncol 29 (4): 888-894, 2018. : Trastuzumab emtansine for HER2-positive advanced breast cancer. Carey LA, Berry DA, Cirrincione CT, et al. : Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. J Clin Oncol 39 (28): 3171-3181, 2021. 13 Some scholars have demonstrated that J Clin Oncol 26 (10): 1664-70, 2008. : The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. One patient in the sacituzumab govitecan group died of a treatment-related adverse event (septic shock related to neutropenic colitis). Multifocal breast cancer: Definition, staging, and treatment J Clin Oncol 23 (31): 7794-803, 2005. With a median follow-up of 50 months, the median OS was 40.8 months in the control group versus 56.5 months in the pertuzumab group (HR favoring pertuzumab group, 0.68; 95% CI, 0.560.84; Median OS was 56.5 months in the pertuzumab group compared with 40.8 months in the placebo group (HR, 0.68; 95% CI, 0.570.84; The toxicity profile was similar in both treatment groups, with no increase in cardiac toxic effects seen in the pertuzumab combination arm. placebo (8.2% vs. 13.4%; With In this cohort, median PFS was 11 months in the alpelisib-plus-fulvestrant arm compared with 5.7 months in the placebo-plus-fulvestrant arm (HR, PFS did not differ between arms in the cohort of participants without. Approximately 32% of patients with ipsilateral supraclavicular node involvement and no evidence of distant metastases (pN3c) had prolonged disease-free survival (DFS) at 10 years with combined-modality therapy. Arimidex Study Group. Cancer 49 (5): 835-9, 1982. : Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. J Clin Oncol 29 (2): 149-56, 2011. Cochrane Database Syst Rev 3: CD003368, 2006. Lancet Oncol 19 (1): 127-138, 2018. : Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. WebKeywrds: Multicentric; Multifocal; Infiltrating Ductal Carcinoma; Hormone Receptors; Breast Cancer we treateda surgicalcarcinoma, perspective.the different and performed presentations ofand simple and receptormastectomy.in multifocal Introduction Background carcinomaa presentation multicentricCasePresentation Goodwin A, Parker S, Ghersi D, et al. : Prognosis following local recurrence in the conservatively treated breast cancer patient. Treatment of DCIS has a high likelihood of success, in most instances removing the tumor and preventing any recurrence. or Multicentric Breast Cancer: Understanding Its Other common adverse events included nausea, arthralgia, fatigue, and alopecia. 9 Thus, for the purpose of obtaining a simple and consistent measurement, the actual tumor burden is underestimated because Ductal carcinoma in situ does not have specific symptoms such a Presence or absence of comorbid medical conditions. Vidula N, Yau C, Rugo HS: Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics. Carmichael J, Walling J: Advanced breast cancer: investigational role of gemcitabine. therapy, and tamoxifen (20 mg qd for 5 years).[. Houghton J, George WD, Cuzick J, et al. : Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. : Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. Yardley DA, Ismail-Khan RR, Melichar B, et al. : Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. Lancet Oncol 18 (6): 732-742, 2017. Lancet Oncol 19 (4): 474-485, 2018. OS between the two arms was not different. Andr F, Ciruelos E, Rubovszky G, et al. : Lapatinib plus capecitabine for HER2-positive advanced breast cancer. Oncologist 25 (2): e243-e251, 2020. During a lumpectomy, a surgeon removes the cancerous cells while saving as much of the surrounding healthy breast tissue as possible. Burstein HJ: Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer. Kuukasjrvi T, Kononen J, Helin H, et al. : Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). intracranial or spinal cord metastases. N Engl J Med 385 (5): 395-405, 2021. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. Cancer 75 (6): 1219-22; discussion 1223-7, 1995. Grade 1 to 2 nausea, infection, fatigue, and diarrhea were also noted. Lancet Oncol 19 (7): 904-915, 2018. N Engl J Med 375 (20): 1925-1936, 2016. Lenihan D, Suter T, Brammer M, et al. : Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). Bergh J, Jnsson PE, Lidbrink EK, et al. Cancer 91 (1): 9-16, 2001. J Clin Oncol 31 (11): 1398-404, 2013. : Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. : Combination anastrozole and fulvestrant in metastatic breast cancer. treatment Seidman AD: Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism? cyclophosphamide or paclitaxel) or the same chemotherapy plus trastuzumab.[. Powles T, Paterson A, McCloskey E, et al. N Engl J Med 366 (2): 109-19, 2012. Bone-modifying therapy, for patients with bone metastases. Correa C, McGale P, Taylor C, et al. Lancet Oncol 21 (1): 60-72, 2020. : MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. : Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. Prospective studies are needed to confirm these findings. The hoped-for outcome of NACT is a pathological Final OS outcomes for this trial have not yet been reported. J Clin Oncol 36 (32): 3259-3268, 2018. J Clin Oncol 32 (13): 1365-83, 2014. N Engl J Med 382 (7): 597-609, 2020. : Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. J Am Coll Surg 203 (4): 469-74, 2006. : The influence of margin width on local control of ductal carcinoma in situ of the breast. In an analysis done after 5 more years of follow-up, the observed benefits of combined therapy were still present, and the level of significance with respect to OS was greater (HR, 0.82; 95% CI, 0.690.98; In contrast, the FACT trial , which enrolled 514 patients, found no difference in either disease-free survival (DFS) (HR, 0.99; 95% CI, 0.811.20; The primary end point was PFS by blinded independent central review. : Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. : Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. Vriens BE, Aarts MJ, de Vries B, et al. : Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Drug-related interstitial lung disease or pneumonitis occurred in 12.1% of the patients who received trastuzumab deruxtecan; 0.8% had grade 5 events. tamoxifen group had fewer breast cancer events at 5 years than did those treated with a De Placido S, Gallo C, De Laurentiis M, et al. Ann Oncol 32 (8): 983-993, 2021. J Clin Oncol 40 (25): 2946-2956, 2022. Berg CD, Swain SM: Results of Concomitantly Administered Chemoradiation for Locally Advanced Noninflammatory Breast Cancer. At a median follow-up of 7.2 months in the T-DM1 group and 6.5 months in the physicians-choice group, median PFS was 6.2 months in the T-DM1 group and 3.3 months in the physicians-choice group (HR, 0.528; 95% CI, 0.4220.661; OS was significantly longer with trastuzumab emtansine versus the treatment of physicians choice (median OS, 22.7 months vs. 15.8 months; HR, 0.68; 95% CI, 0.540.85; The role of T-DM1 as first-line treatment of metastatic HER2-overexpressed breast cancer was evaluated in the phase III. Semin Oncol 26 (4 Suppl 12): 1-10, 1999. Goss PE, Ingle JN, Pritchard KI, et al. Lancet Oncol 15 (6): 580-91, 2014. : Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. Ann Surg Oncol 19 (10): 3177-84, 2012. Slamon DJ, Neven P, Chia S, et al. multifocal and multicentric breast cancer A 6.9 month difference in median OS favoring the palbociclib-fulvestrant arm (34.9 months vs. 28.0 months) was found, which did not reach statistical significance (HR, 0.81; 95% CI, 0.641.03. WebMultifocal multicentric breast cancer has traditionally been considered a contraindication to breast conserving surgery because of concerns regarding locoregional control and risk of disease recurrence. This report details the surgical management and clinical reasoning behind lumpectomy for a multicentric breast cancer spanning 5 cm. Introduction. Lyman GH, Temin S, Edge SB, et al. One patient died of pneumonia that was assessed by the investigator to be treatment related. Quilty PM, Kirk D, Bolger JJ, et al. : Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Successful Lumpectomy in a Patient With Multicentric Breast Cancer At the time of final analysis for PFS, the median PFS for the ribociclib group was 20.5 months versus 12.8 months in the placebo group (HR, 0.593; 95% CI, 0.4800.732; OS was superior in the ribociclib group (HR, 0.724; 95% CI, 0.5680.924; Adverse events were similar to those in other studies of CDK4/6 inhibitors. Diras V, Miles D, Verma S, et al. : Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. : Ductal carcinoma in situ: a proposal for a new classification. : Response - blunting the counterpoint. [, Breast: In the Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer (, In ER-negative patients, the HR for DFS for chemotherapy versus no chemotherapy was 0.29 (95% CI, 0.130.67; 10 years DFS, 70% vs. 34%), whereas in ER-positive patients, the HR was 1.07 (95% CI, 0.572.00; 10 years DFS, 50% vs. 59%). Tormey DC, Gelman R, Band PR, et al. : Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. : Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. treatment Sledge GW, Toi M, Neven P, et al. Silverstein MJ, Lagios MD, Craig PH, et al. J Clin Oncol 14 (9): 2584-9, 1996. Treatment Multicentric Breast Cancer The overall response rate was 35% in the sacituzumab govitecan arm and 5% in the chemotherapy arm. N Engl J Med 387 (3): 217-226, 2022. multicentric breast cancer J Clin Oncol 19 (3): 628-33, 2001. There was no grade 4 diarrhea. Lancet Oncol 15 (4): 474-82, 2014. Multicentric Breast Cancer Grade 3 to 4 neutropenia occurred in 61% of patients in the ribociclib group and 4% of patients in the placebo group. Ann Oncol 10 (5): 553-60, 1999. Keywords: multicentric breast cancer, mastectomy, lumpectomy, breast conserving. J Clin Oncol 35 (2): 141-148, 2017. JAMA Oncol 6 (1): 116-124, 2020. Lancet Oncol 20 (3): 339-351, 2019. The sequential primary end points were PFS by central review followed by OS. In this prospective multi-institutional trial, SNB-feasibility and accuracy was evaluated in 142 patients with multicentric cancer from the Austrian Sentinel Node Study Group (ASNSG) and compared with data from 3,216 Neoadjuvant therapy also permits evaluation of the effectiveness of systemic therapy, which is increasingly used to guide adjuvant treatment recommendations. : Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. CA Cancer J Clin 61 (4): 212-36, 2011 Jul-Aug. Fisher ER, Dignam J, Tan-Chiu E, et al.
Christian Schools Grand Rapids,
Dr Gordon Orthopedic Surgeon,
Ncl Athens Excursions,
The Cookery Fort Worth,
Articles T